Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization
I'm PortAI, I can summarize articles.
Exicure Inc. announced positive Phase 2 trial results for burixafor in multiple myeloma stem cell mobilization, achieving the primary endpoint in 90% of participants. The study showed favorable safety and rapid mobilization kinetics, with peak CD34+ cell levels within one hour of administration. Results were presented at the 2025 ASH Annual Meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments